Ameritas Advisory Services LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 335 shares of the pharmaceutical company’s stock, valued at approximately $107,000.
A number of other institutional investors have also recently made changes to their positions in the business. BerganKDV Wealth Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 0.5% in the first quarter. BerganKDV Wealth Management LLC now owns 6,421 shares of the pharmaceutical company’s stock valued at $2,023,000 after purchasing an additional 31 shares in the last quarter. TCI Wealth Advisors Inc. grew its holdings in shares of Vertex Pharmaceuticals by 22.6% in the fourth quarter. TCI Wealth Advisors Inc. now owns 179 shares of the pharmaceutical company’s stock valued at $52,000 after purchasing an additional 33 shares in the last quarter. VELA Investment Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 0.4% in the fourth quarter. VELA Investment Management LLC now owns 8,837 shares of the pharmaceutical company’s stock valued at $2,552,000 after purchasing an additional 34 shares in the last quarter. Condor Capital Management grew its holdings in Vertex Pharmaceuticals by 0.5% during the 4th quarter. Condor Capital Management now owns 7,222 shares of the pharmaceutical company’s stock worth $2,086,000 after acquiring an additional 36 shares in the last quarter. Finally, SJS Investment Consulting Inc. grew its holdings in Vertex Pharmaceuticals by 61.9% during the 4th quarter. SJS Investment Consulting Inc. now owns 102 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 39 shares in the last quarter. Institutional investors and hedge funds own 91.37% of the company’s stock.
Analyst Ratings Changes
Several research analysts have commented on VRTX shares. Barclays boosted their price target on shares of Vertex Pharmaceuticals from $342.00 to $384.00 in a report on Tuesday, May 2nd. Royal Bank of Canada boosted their price objective on shares of Vertex Pharmaceuticals from $315.00 to $323.00 in a research report on Thursday, June 8th. Robert W. Baird boosted their price objective on shares of Vertex Pharmaceuticals from $280.00 to $325.00 in a research report on Tuesday, May 2nd. Bank of America boosted their price objective on shares of Vertex Pharmaceuticals from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, July 21st. Finally, Sanford C. Bernstein boosted their price objective on shares of Vertex Pharmaceuticals from $344.00 to $363.00 in a research report on Wednesday, May 3rd. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $359.00.
Insider Transactions at Vertex Pharmaceuticals
In related news, Director Bruce I. Sachs sold 11,250 shares of the stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $356.75, for a total value of $4,013,437.50. Following the sale, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $14,270,000. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Bruce I. Sachs sold 11,250 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $356.75, for a total transaction of $4,013,437.50. Following the completion of the transaction, the director now directly owns 40,000 shares in the company, valued at approximately $14,270,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Stuart A. Arbuckle sold 8,603 shares of the stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $349.00, for a total value of $3,002,447.00. Following the sale, the chief operating officer now owns 56,556 shares in the company, valued at approximately $19,738,044. The disclosure for this sale can be found here. Insiders have sold a total of 41,980 shares of company stock valued at $14,789,852 in the last ninety days. 0.30% of the stock is currently owned by company insiders.
Vertex Pharmaceuticals Stock Down 1.7 %
Shares of Vertex Pharmaceuticals stock opened at $351.91 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.11 and a current ratio of 4.28. Vertex Pharmaceuticals Incorporated has a one year low of $271.61 and a one year high of $367.00. The company has a market cap of $90.63 billion, a P/E ratio of 28.02, a PEG ratio of 2.70 and a beta of 0.51. The firm has a fifty day moving average of $342.87 and a two-hundred day moving average of $322.80.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings results on Monday, May 1st. The pharmaceutical company reported $3.05 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.54. Vertex Pharmaceuticals had a net margin of 35.40% and a return on equity of 25.06%. The business had revenue of $2.37 billion for the quarter, compared to analysts’ expectations of $2.34 billion. During the same period in the prior year, the company posted $3.16 EPS. The business’s revenue for the quarter was up 13.2% on a year-over-year basis. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 13.06 earnings per share for the current year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations.
Featured Articles
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Vertex Pharmaceuticals wasn’t on the list.
While Vertex Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
